Long-term safety and efficacy of upadacitinib in Japanese patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: 5-year results from the SELECT-SUNRISE randomised controlled trial
Upadacitinib showed sustained efficacy with no new safety signals identified through 5 years of treatment and is a long-term treatment option for Japanese patients with rheumatoid arthritis and csDMARDs-IR.
Authors
- Yoshiya Tanaka (ORCID: https://orcid.org/0000-0002-0807-7139)
- Sumi Chonan
- Heidi S. Camp (ORCID: https://orcid.org/0009-0003-2632-015X)
- Kunihiro Yamaoka (ORCID: https://orcid.org/0000-0001-8858-9435)
- Yuko Konishi
- Hideto Kameda (ORCID: https://orcid.org/0000-0002-4330-5782)
- Kimitoshi Ikeda
- Tsutomu Takeuchi (ORCID: https://orcid.org/0000-0003-1111-8218)
- Mitsuhiro Kawano
- Motohiro Oribe
Institutions
- Toho University (JP)
- Kanazawa Medical University (JP)
- University of Occupational and Environmental Health Japan (JP)
- Keio University (JP)
- AbbVie (United States) (US)
- ABB (Japan) (JP)
- AbbVie (Japan)
- Kitasato University (JP)
- Saitama Medical University (JP)
Publication Details
- Journal
- RMD Open
- Published
- 2025-10-01
- DOI
- https://doi.org/10.1136/rmdopen-2025-006213
- Primary Topic
- Rheumatoid Arthritis Research and Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- University of Pennsylvania